This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Steven M. Podos, MD; Janet B. Serle, MD

Arch Ophthalmol. 1991;109(1):38-40.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The carbonic anhydrase inhibitor, Diamox, is an effective agent in lowering intraocular pressure in man when administered in oral doses of 500 to 1000 mg." This one sentence summarized a 2 page initial article on this subject written by a single author, Bernard Becker, in 1954.¹ A year later, Green and Leopold² noted that acetazolamide given subconjunctivally to rabbits did not reduce intraocular pressure. Thus began a 35-year search for an active topically administered carbonic anhydrase inhibitor, a search characterized by stops and spurts, one that is reaching fruition thanks largely to the efforts of Thomas Maren of the University of Florida.

See also pp 46 and 50.

Systemically administered carbonic anhydrase inhibitors, even when properly utilized in the lowest dose possible to achieve the therapeutic goal in each patient with glaucoma, produce a well-known litany of side effects, including paresthesias, gastrointestinal upset, weight loss, fatigue, depression, impotence, . . . [Full Text PDF of this Article]

Author Affiliations
New York, NY

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?